Brief: Akeso Says Ivonescimab Meets Os Key Secondary Endpoint In Harmoni-2 Study
03/09/2026 02:31
BRIEF-Akeso Says Ivonescimab Meets Os Key Secondary Endpoint In Harmoni-2 Study Sept 3 (Reuters) - Akeso Inc 9926.HK:
IVONESCIMAB MEETS OS KEY SECONDARY ENDPOINT IN HARMONI-2 STUDY
Further company coverage: 9926.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals